- Home
- VGI vs QNCX Comparison
VGI vs QNCX Comparison
Compare VGI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGI
- QNCX
- Stock Information
- Founded
- VGI 2012
- QNCX 2012
- Country
- VGI United States
- QNCX United States
- Employees
- VGI N/A
- QNCX N/A
- Industry
- VGI Investment Managers
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VGI Finance
- QNCX Health Care
- Exchange
- VGI Nasdaq
- QNCX Nasdaq
- Market Cap
- VGI 91.4M
- QNCX 92.3M
- IPO Year
- VGI N/A
- QNCX 2019
- Fundamental
- Price
- VGI $7.68
- QNCX $1.66
- Analyst Decision
- VGI
- QNCX Strong Buy
- Analyst Count
- VGI 0
- QNCX 4
- Target Price
- VGI N/A
- QNCX $9.50
- AVG Volume (30 Days)
- VGI 46.0K
- QNCX 147.2K
- Earning Date
- VGI 01-01-0001
- QNCX 11-13-2024
- Dividend Yield
- VGI 12.66%
- QNCX N/A
- EPS Growth
- VGI N/A
- QNCX N/A
- EPS
- VGI N/A
- QNCX N/A
- Revenue
- VGI N/A
- QNCX N/A
- Revenue This Year
- VGI N/A
- QNCX N/A
- Revenue Next Year
- VGI N/A
- QNCX N/A
- P/E Ratio
- VGI N/A
- QNCX N/A
- Revenue Growth
- VGI N/A
- QNCX N/A
- 52 Week Low
- VGI $6.68
- QNCX $0.51
- 52 Week High
- VGI $7.99
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- VGI 44.73
- QNCX 40.36
- Support Level
- VGI $7.50
- QNCX $1.70
- Resistance Level
- VGI $7.70
- QNCX $1.78
- Average True Range (ATR)
- VGI 0.11
- QNCX 0.13
- MACD
- VGI 0.01
- QNCX -0.03
- Stochastic Oscillator
- VGI 60.00
- QNCX 2.56
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objectives by capitalizing on opportunities across undervalued areas of the global bond markets.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.